Менопаузальная гормональная терапия: курс на повышение эффективности

1. Lobo RA, Davis SR, de Villiers TJ et al. Prevention of diseases after menopause. Climacteric 2014; 17: 540–56.
2. Baber RJ, Panay N, Fenton A; IMS Writing Group (2016). IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19 (2): 109–50.
3. Harlow SD, Gass M, Hall JE et al; STRAW+10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97 (4): 1159–68. DOI: 10.1210/jc.2011-3362
4. Abdulnour J, Doucet E, Brochu M et al. The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa New Emerging Team group study. Menopause 2012; 19 (7): 760–7.
5. Dubnov-Raz G, Pines A, Berry EM. Diet and lifestyle in managing postmenopausal obesity. Climacteric 2007; 10 (Suppl. 2): 38–41.
6. Luoto R, Moilanen J, Heinonen R et al. Effect of aerobic training on hot flushes and quality of life – a randomized controlled trial. Ann Med 2012; 44: 616–26.
7. Goodpaster BH, Park SW, Harris TB et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 2006; 61: 1059–64.
8. Grindler NM, Santoro NF. Menopause and exercise. Menopause 2015; 22 (12): 1351–8. DOI: 10.1097/GME.0000000000000536
9. Chen Z, Bassford T, Green SB et al. Postmenopausal hormone therapy and body composition – a substudy of the estrogen plus progestin trial of the Women's Health Initiative. Am J Clin Nutr 2005; 82 (3): 651–6.
10. Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int 2013; 19 (4): 155–62.
11. Cody JD, Jacobs ML, Richardson K et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012; 10: CD001405. DOI: 10.1002/14651858.CD001405.pub3
12. Moore K, Dumoulin C, Bradley C et al. Adult conservative management. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Paris: Health Publications Ltd, 2013; p. 1101–228.
13. Villiers TJ. Bone health and osteoporosis in postmenopausal women. Best Pract Res Clin Obstet Gynaecol 2009; 23: 73–85.
14. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following fracture. JAMA 2001; 285: 320–3.
15. Karsdal MA, Bay-Jensen AC, Henriksen K, Christiansen C. The pathogenesis of osteoarthritis involves bone, cartilage and synovial inflammation: may estrogen be a magic bullet? Menopause Int 2012; 18: 139–46.
16. Welton AJ, Vickers MR, Kim J et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008; 337: 550–3.
17. Cirillo DJ, Wallace RB, Wu L, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health Initiative. Arthritis Rheum 2006; 54: 3194–204.
18. Masuda Y, Hirao T, Mizunuma H. Improvement of skin surface texture by topical estradiol treatment in climacteric women. J Dermatol Treat 2013; 24: 312–17. 
19. Verdier-Se´vrain S. Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators. Climacteric 2007; 10: 289–97.
20. Maruthur NM, Wang N-Y, Appel LJ. Lifestyle interventions reduce coronary artery disease risk. Results from the PREMIER trial. Circulation 2009; 119: 2026–31.
21. Hodis HN, Collins P, Mack WJ et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012; 15: 217–28.
22. Lethbridge-Çejku M, Vickerie J. Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2003. Vital Health Stat 2005; 10: 225.
23. Lisabeth LD, Beiser AS, Brown DL et al. Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke 2009; 40: 1044–9.
24. Rocca WA, Grossardt BR, Miller VM et al. Premature menopause or early menopause and risk of ischemic stroke. Menopause 2012; 19 (3): 272–7. DOI: 10.1097/gme.0b013e31822a9937
25. Henderson VW, Lobo RA. Hormone therapy and the risk of stroke: perspectives 10 years after the Women’s Health Initiative trials. Climacteric 2012; 15: 229–34.
26. Lobo RA, Clarkson TB. Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause 2011; 18: 237–40.
27. Laliberté F, Dea K, Duh MS et al. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011; 18: 1052–9.
28. Scarabin PY. Hormone therapy and venous thromboembolism among postmenopausal women. Front Horm Res 2014; 43: 21–32.
29. Curb JD, Prentice RL, Bray PF et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166: 772–80.
30. Manson JE, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013; 310: 1353–68.
31. Smith NL, Blondon M, Wiggins KL et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med 2014; 174: 25–31.
32. Olie V, Plu-Bureau G, Conard J et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011; 18: 488–93.
33. Canonico M, Oger E, Conard J et al. EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006; 4: 1259–65.
34. Cushman M, Kuller LH, Prentice R et al. Women’s Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573–80.
35. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 1227–31.
36. Straczek C, Oger E, Yon de Jonage-Canonico MB et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112: 3495–500.
37. Blondon M, Van Hylckama Vlieg A, Wiggins KL et al. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers. J Thromb Haemost 2014; 12: 879–86.
38. Canonico M, Fournier A, Carcaillon L et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010; 30: 340–5.
39. Henderson VW, Sherwin BB. Surgical versus natural menopause: cognitive issues. Menopause 2007; 14: 572–9.
40. Chlebowski RT, Hendrix SL, Langer RD et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA 2003; 289: 3243–53.
41. Anderson GL, Chlebowski RT, Rossouw JE et al. Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006; 55: 103–15.
42. Somboonporn W, Panna S, Temtanakitpaisan T et al. Effects of the levonorgestrelreleasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011; 18: 1060–6.
43. Anderson GL, Chlebowski RT, Aragaki AK et al. Conjugated equine o estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012; 13: 476–86.
44. Lundstrom E, Christow A, Kersemaekers W et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002; 186: 717–22.
45. Kenemans P, Bundred NJ, Foidart JM et al. LIBERATE Study Group. Safety and efficacy of tibolone in breastcancer patients with vasomotor symptoms: a doubleblind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135–46.
46. Gupta JK, Chien PF, Voit D et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand 2002; 81: 799–816.
47. Weiderpass E, Adami HO, Baron JA et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131–7.
48. Somboonporn W, Panna S, Temtanakitpaisan T et al. Effects of the levonorgestrel releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011; 18: 1060–6.
49. Weber R, Brenck J, Diener HC. Antiplatelet therapy in cerebrovascular disorders. Handb Exp Pharmacol 2012; 210: 519–46.
50. Massaro M, Scoditti E, Carluccio MA et al. Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes. Thromb Haemost 2013; 109 (2): 280–9.
51. Chen YC, Chen CH, Ko WS et al. Dipyridamole inhibits lipopolysaccharide-induced cyclooxygenase-2 and monocyte chemoattractant protein-1 via heme oxygenase-1-mediated reactive oxygen species reduction in rat mesangial cells. Eur J Pharmacol 2011; 650 (1): 445–50.
52. Eisert WG. Dipyridamole in antithrombotic treatment. Adv Cardiol 2012; 47: 78–86.
53. Ge SM, Zhan DL, Zhang SH et al. Reverse screening approach to identify potential anti-cancer targets of dipyridamole. Am J Transl Res. 2016; 8 (12): 5187–98. eCollection 2016.
54. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem 2015; 15 (9): 822–9.
55. Goda AE, Yoshida T, Horinaka M, Yasuda T. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27 (24): 3435–45.
56. Choudhary S, Sood S. Dipyridamole intervention of breast cell carcinogenesis. Mol Carcinog 2014; 53 (3): 243–52.
57. Balakumar P, Nyo YH, Renushia R, Raaginey D. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacol Res 2014; 87: 144–50.
58. Инструкции по медицинскому применению препаратов Курантил® N25(ПN013897/01-280312), Курантил® N75 (ПN013899/01-280312). / Instruktsii po meditsinskomu primeneniiu preparatov Kurantil® N25(PN013897/01-280312), Kurantil® N75 (PN013899/01-280312). [in Russian]

________________________________________________

1. Lobo RA, Davis SR, de Villiers TJ et al. Prevention of diseases after menopause. Climacteric 2014; 17: 540–56.
2. Baber RJ, Panay N, Fenton A; IMS Writing Group (2016). IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19 (2): 109–50.
3. Harlow SD, Gass M, Hall JE et al; STRAW+10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97 (4): 1159–68. DOI: 10.1210/jc.2011-3362
4. Abdulnour J, Doucet E, Brochu M et al. The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa New Emerging Team group study. Menopause 2012; 19 (7): 760–7.
5. Dubnov-Raz G, Pines A, Berry EM. Diet and lifestyle in managing postmenopausal obesity. Climacteric 2007; 10 (Suppl. 2): 38–41.
6. Luoto R, Moilanen J, Heinonen R et al. Effect of aerobic training on hot flushes and quality of life – a randomized controlled trial. Ann Med 2012; 44: 616–26.
7. Goodpaster BH, Park SW, Harris TB et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 2006; 61: 1059–64.
8. Grindler NM, Santoro NF. Menopause and exercise. Menopause 2015; 22 (12): 1351–8. DOI: 10.1097/GME.0000000000000536
9. Chen Z, Bassford T, Green SB et al. Postmenopausal hormone therapy and body composition – a substudy of the estrogen plus progestin trial of the Women's Health Initiative. Am J Clin Nutr 2005; 82 (3): 651–6.
10. Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int 2013; 19 (4): 155–62.
11. Cody JD, Jacobs ML, Richardson K et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012; 10: CD001405. DOI: 10.1002/14651858.CD001405.pub3
12. Moore K, Dumoulin C, Bradley C et al. Adult conservative management. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Paris: Health Publications Ltd, 2013; p. 1101–228.
13. Villiers TJ. Bone health and osteoporosis in postmenopausal women. Best Pract Res Clin Obstet Gynaecol 2009; 23: 73–85.
14. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following fracture. JAMA 2001; 285: 320–3.
15. Karsdal MA, Bay-Jensen AC, Henriksen K, Christiansen C. The pathogenesis of osteoarthritis involves bone, cartilage and synovial inflammation: may estrogen be a magic bullet? Menopause Int 2012; 18: 139–46.
16. Welton AJ, Vickers MR, Kim J et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008; 337: 550–3.
17. Cirillo DJ, Wallace RB, Wu L, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health Initiative. Arthritis Rheum 2006; 54: 3194–204.
18. Masuda Y, Hirao T, Mizunuma H. Improvement of skin surface texture by topical estradiol treatment in climacteric women. J Dermatol Treat 2013; 24: 312–17. 
19. Verdier-Se´vrain S. Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators. Climacteric 2007; 10: 289–97.
20. Maruthur NM, Wang N-Y, Appel LJ. Lifestyle interventions reduce coronary artery disease risk. Results from the PREMIER trial. Circulation 2009; 119: 2026–31.
21. Hodis HN, Collins P, Mack WJ et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012; 15: 217–28.
22. Lethbridge-Çejku M, Vickerie J. Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2003. Vital Health Stat 2005; 10: 225.
23. Lisabeth LD, Beiser AS, Brown DL et al. Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke 2009; 40: 1044–9.
24. Rocca WA, Grossardt BR, Miller VM et al. Premature menopause or early menopause and risk of ischemic stroke. Menopause 2012; 19 (3): 272–7. DOI: 10.1097/gme.0b013e31822a9937
25. Henderson VW, Lobo RA. Hormone therapy and the risk of stroke: perspectives 10 years after the Women’s Health Initiative trials. Climacteric 2012; 15: 229–34.
26. Lobo RA, Clarkson TB. Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause 2011; 18: 237–40.
27. Laliberté F, Dea K, Duh MS et al. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011; 18: 1052–9.
28. Scarabin PY. Hormone therapy and venous thromboembolism among postmenopausal women. Front Horm Res 2014; 43: 21–32.
29. Curb JD, Prentice RL, Bray PF et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166: 772–80.
30. Manson JE, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013; 310: 1353–68.
31. Smith NL, Blondon M, Wiggins KL et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med 2014; 174: 25–31.
32. Olie V, Plu-Bureau G, Conard J et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011; 18: 488–93.
33. Canonico M, Oger E, Conard J et al. EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006; 4: 1259–65.
34. Cushman M, Kuller LH, Prentice R et al. Women’s Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573–80.
35. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 1227–31.
36. Straczek C, Oger E, Yon de Jonage-Canonico MB et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112: 3495–500.
37. Blondon M, Van Hylckama Vlieg A, Wiggins KL et al. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers. J Thromb Haemost 2014; 12: 879–86.
38. Canonico M, Fournier A, Carcaillon L et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010; 30: 340–5.
39. Henderson VW, Sherwin BB. Surgical versus natural menopause: cognitive issues. Menopause 2007; 14: 572–9.
40. Chlebowski RT, Hendrix SL, Langer RD et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA 2003; 289: 3243–53.
41. Anderson GL, Chlebowski RT, Rossouw JE et al. Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006; 55: 103–15.
42. Somboonporn W, Panna S, Temtanakitpaisan T et al. Effects of the levonorgestrelreleasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011; 18: 1060–6.
43. Anderson GL, Chlebowski RT, Aragaki AK et al. Conjugated equine o estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012; 13: 476–86.
44. Lundstrom E, Christow A, Kersemaekers W et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002; 186: 717–22.
45. Kenemans P, Bundred NJ, Foidart JM et al. LIBERATE Study Group. Safety and efficacy of tibolone in breastcancer patients with vasomotor symptoms: a doubleblind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135–46.
46. Gupta JK, Chien PF, Voit D et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand 2002; 81: 799–816.
47. Weiderpass E, Adami HO, Baron JA et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131–7.
48. Somboonporn W, Panna S, Temtanakitpaisan T et al. Effects of the levonorgestrel releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011; 18: 1060–6.
49. Weber R, Brenck J, Diener HC. Antiplatelet therapy in cerebrovascular disorders. Handb Exp Pharmacol 2012; 210: 519–46.
50. Massaro M, Scoditti E, Carluccio MA et al. Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes. Thromb Haemost 2013; 109 (2): 280–9.
51. Chen YC, Chen CH, Ko WS et al. Dipyridamole inhibits lipopolysaccharide-induced cyclooxygenase-2 and monocyte chemoattractant protein-1 via heme oxygenase-1-mediated reactive oxygen species reduction in rat mesangial cells. Eur J Pharmacol 2011; 650 (1): 445–50.
52. Eisert WG. Dipyridamole in antithrombotic treatment. Adv Cardiol 2012; 47: 78–86.
53. Ge SM, Zhan DL, Zhang SH et al. Reverse screening approach to identify potential anti-cancer targets of dipyridamole. Am J Transl Res. 2016; 8 (12): 5187–98. eCollection 2016.
54. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem 2015; 15 (9): 822–9.
55. Goda AE, Yoshida T, Horinaka M, Yasuda T. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27 (24): 3435–45.
56. Choudhary S, Sood S. Dipyridamole intervention of breast cell carcinogenesis. Mol Carcinog 2014; 53 (3): 243–52.
57. Balakumar P, Nyo YH, Renushia R, Raaginey D. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacol Res 2014; 87: 144–50.
58. Instruktsii po meditsinskomu primeneniiu preparatov Kurantil® N25(PN013897/01-280312), Kurantil® N75 (PN013899/01-280312). [in Russian]

А.Л.Унанян*1, И.С.Сидорова1, Л.Н.Аминова2, В.А.Алимов2, А.Д.Никонец1, Ю.В.Чушков1, А.В.Щукина3, Д.В.Бабурин1

1. ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2. Клиническая больница №2 МЕДСИ. 125284, Россия, Москва, 2-й Боткинский пр., д. 5;
3. ГБУЗ «Городская поликлиника №68» Департамента здравоохранения г. Москвы. 119180, Россия, Москва, ул. Малая Якиманка, д. 22, стр. 1
*9603526@mail.ru

________________________________________________

A.L.Unanyan*1, I.S.Sidorova1, L.N.Aminova2, V.A.Alimov2, A.D.Nikonets1, Yu.V.Chushkov1, A.V.Shchukina3, D.V.Baburin1

1. I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaya, d. 8, str. 2;
2. Clinical Hospital №2 MEDSI. 125284, Russian Federation, Moscow, 2-i Botkinskii pr., d. 5;
3. Сity Hospital №68 of the Department of Health of Moscow. 119180, Russian Federation, Moscow, ul. Malaya Yakimanka, d. 22, str. 1
*9603526@mail.ru